Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy

OBJECTIVE: Nearly 5% of patients with breast cancer carry germline BRCA mutations, which are more common in triple-negative breast cancer (TNBC). Previous clinical trials demonstrated the therapeutic efficacy of poly (ADP-ribose) polymerase inhibitors (PARPis) against BRCA-mutated metastatic breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zheling, Wang, Xiao, Li, Xiao, Zhou, Yucheng, Chen, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164563/
https://www.ncbi.nlm.nih.gov/pubmed/33541181
http://dx.doi.org/10.1177/0300060521991019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164563/
https://www.ncbi.nlm.nih.gov/pubmed/33541181
http://dx.doi.org/10.1177/0300060521991019

Ejemplares similares